Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fulvestrant + sapanisertib
- Development stage
- Unknown
- Lead developer
- Millennium Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intramuscular, Oral
01
Overview
Combination therapy consisting of fulvestrant and sapanisertib. Fulvestrant is an estrogen receptor antagonist, while sapanisertib is a selective dual inhibitor of mTOR complexes 1 and 2 (TORC1 and TORC2). This combination was investigated for the treatment of estrogen receptor-positive (ER+)/HER2-negative advanced or metastatic breast cancer in postmenopausal women who experienced disease progression during or after aromatase inhibitor treatment. The combination aims to overcome endocrine resistance by simultaneously targeting the estrogen receptor pathway and the PI3K/AKT/mTOR signaling pathway.
- Other names
- FTH-003FTH003FTH 003HY-13328HY13328HY 13328CB-228CB228CB 228
02
Targets
Mechanistic target of rapamycin kinase complex 2Mechanistic target of rapamycin complex 1ESR1 (ERα)
Beyond the preview
Go deeper on fulvestrant + sapanisertib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fulvestrant + sapanisertib.